GlaxoSmithKline To Pay Out $105 Million To Settle U.S. Claims Of Improper Marketing

British drugmaker GlaxoSmithKline Plc (GSK.L) has agreed to pay $105 million (62.7 million pounds) to settle allegations by 44 U.S. states and the District of Columbia that it promoted its medicines for unapproved uses, several states attorneys general announced on Wednesday. Glaxo was accused by the states of illegally marketing its big-selling asthma drug Advair for use by mild asthma sufferers and the antidepressants Paxil and Wellbutrin for use by children and teenagers without FDA approval. Several antidepressants have been associated with increased risk of suicide in younger patients. "GlaxoSmithKline put its business interests ahead of what was best for vulnerable patients," Illinois Attorney General Lisa Madigan said in a statement.

Help employers find you! Check out all the jobs and post your resume.